Eylea is prescribed to prevent vision loss from conditions like wet age-related macular degeneration and diabetic macular edema by targeting and blocking a protein called vascular endothelial growth ...
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback